Blocking of Interleukin-17 during Reactivation of Experimental Arthritis Prevents Joint Inflammation and Bone Erosion by Decreasing RANKL and Interleukin-1

Documenti analoghi

• Interleukin-18 Promotes Joint Inflammation and Induces Interleukin-1-Driven Cartilage Destruction
  di: Joosten, Leo A.B., et al.
  Pubblicazione: (2004)
• Neutralizing synovial RANKL by local OPG gene therapy in collagen-induced arthritis prevents cartilage erosion through induction of a non-destructive type 2 synovitis
  di: Lubberts, E, et al.
  Pubblicazione: (2004)
• IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion
  di: Lubberts, Erik, et al.
  Pubblicazione: (2000)
• Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis
  di: van Nieuwenhuijze, Annemarie E. M., et al.
  Pubblicazione: (2015)
• Neutralizing IL-17 during re-activation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and IL-1
  di: Koenders, MI, et al.
  Pubblicazione: (2005)